Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gtp. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.65 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.63 |
| ▸ | KRAS | P01116 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | HINT1 | P49773 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL1332521 | 0.99 | NT5E (0.71) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL2194831 | 0.99 | NT5E (0.71) | NT5EBLMTGM2PMP22CYP2C19 | |
| SCHEMBL28001540 | 0.99 | NT5E (0.71) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL29480632 | 0.98 | NT5E (0.70) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL28315044 | 0.98 | NT5E (0.70) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL28593121 | 0.98 | NT5E (0.70) | NT5EBLMTGM2PMP22CYP2C19 | |
| SCHEMBL1096046 | 0.97 | NT5E (0.73) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL9113739 | 0.94 | NT5E (0.72) | NT5EBLMTGM2PMP22CYP2C19 | |
| Gtp SCHEMBL20578211 | 0.94 | NT5E (0.72) | NT5EBLMTGM2PMP22CYP2C19 | |
| SCHEMBL28850748 | 0.94 | NT5E (0.72) | NT5EBLMTGM2PMP22CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240396084-A1 | ELECTROLYTE ADDITIVE FOR LITHIUM-ION BATTERY AND PREPARATION METHOD AND APPLICATION THEREOF | Hubei Wanrun New Energy Technology Co., Ltd. (CN) | 2024-11-28 | — | — | US | claimed |
| EP-4468436-A2 | ELECTROLYTE ADDITIVE FOR LITHIUM-ION BATTERY AND PREPARATION METHOD AND APPLICATION THEREOF | HUBEI WANRUN NEW ENERGY TECHNOLOGY CO., LTD. (CN) | 2024-11-27 | — | — | EP | claimed |
| US-20240396084-A1 | ELECTROLYTE ADDITIVE FOR LITHIUM-ION BATTERY AND PREPARATION METHOD AND APPLICATION THEREOF | Hubei Wanrun New Energy Technology Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
| EP-4468436-A2 | ELECTROLYTE ADDITIVE FOR LITHIUM-ION BATTERY AND PREPARATION METHOD AND APPLICATION THEREOF | HUBEI WANRUN NEW ENERGY TECHNOLOGY CO., LTD. (CN) | 2024-11-27 | — | — | EP | disclosed |
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | CIBA CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2120846-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
| WO-2002004005-A2 | SHORT PEPTIDES COMPRISING HISTIDINE OR ALANINE AND THEIR THERAPEUTIC USE | KS BIOMEDIX LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
| US-6303588-B1 | APPLYING TO PORTIONS OF THE SKIN OF SUCH PATIENT WHICH HAVE ABNORMAL SKIN CELL METABOLISM BIOACTIVE AGENT COMPRISING ADENOSINE-5-TRIPHOSPHATE, QUANOSINE-5-TRIPHOSPHATE AND PHOSPHINOSITEDES AND BIOLOGICALLY ACCEPTABLE CARRIER | Danielov, Michael M. | 2001-10-16 | — | — | US | disclosed |
| US-5885974-A | DECREASES THE DOSAGE OF BIOACTIVE AGENT NECESSARY, WHEN ADMINISTERED TO A PATIENT WITH ABNORMAL CELL METABOLISM, TO CORRECT THE ABNORMAL CELL METABOLISM AND PROMOTE THE RESUMPTION OF NORMAL CELL METABOLISM | Danielov, Michael M. (US) | 1999-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | MAOA, MAOB, ACMSD | NT5E 2295/4885BLM 1799/4885TGM2 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.